NCT04493060View on ClinicalTrials.gov

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 28, 2020

Primary Completion Date

December 7, 2023

Study Completion Date

June 1, 2025

Conditions
Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Interventions
BIOLOGICAL

Dostarlimab

Given IV

DRUG

Niraparib

Given PO

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER